Dr. Donald Krogstad, professor of tropical medicine at Tulane University School of Public Health and Tropical Medicine, developed a new treatment against drug-resistant strains of the Plasmodium falciparum parasite that causes malaria.
Tulane University researchers have developed a new drug that is effective against non-severe cases of malaria, according to results from an FDA-supervised clinical trial published online in The Lancet Infectious Diseases.
The results are significant as public health experts have long warned that the parasite responsible for most malaria cases, Plasmodium falciparum, is developing resistance to widely used treatments. New medications are needed to build up secondary defenses against drug-resistant strains of the parasite.
The drug, called AQ-13, was able to clear the parasite responsible for the disease within a week, matching the effectiveness of the most widely used treatment regimen.
“The potential long-term implications are bigger than one drug. The conceptual step here is that if you understand the resistance well enough, you may be actually be able to develop others as well.”
Dr. Donald Krogstad
“The clinical trial results are extraordinarily encouraging,” said Dr. Donald Krogstad, senior author and professor of tropical medicine at Tulane University School of Public Health and Tropical Medicine. “Compared to the current first-line recommendation for treatment of malaria, the new drug comes out very well.”
Mosquitoes infected by a parasite spread malaria, causing more than 200 million illnesses across the globe and more than 400,000 deaths annually. For decades, chloroquine was used to treat malaria until Plasmodium falciparum developed resistance. Now, a drug combination — artemether and lumefantrine — is the primary treatment for malaria although resistance is also developing to the drug combination in some countries.
Researchers recruited 66 adult men in Mali with uncomplicated malaria, which is defined as malaria that isn’t life threatening. Half were treated with AQ-13 and the other half received artemether and lumefantrine. Both drug groups had similar cure rates. However, five participants in AQ-13 group left the study or were lost to follow-up and two participants in the artemether/lumefantrine group had late treatment failures with recurrence of their original infections.
Researchers hope to expand testing of the drug to more participants, including women and children, before it can be widely recommended as a new treatment. Krogstad said that the same biotechnology that helped the team develop the new drug has also identified similar drugs that also hold promise against drug-resistant parasites.
Learn more: New Tulane University drug effective against malaria
The Latest on: Malaria
- Global Fund gives SA $547m boost to fight TB, HIV/AIDS and malariaon May 12, 2022 at 11:41 am
Johannesburg - The Global Fund has donated $547m (R8.8bn) towards HIV/AIDS, TB and Malaria programmes in South Africa. The intervention programmes are expected to run from April 2022 to March 2025.
- DR Congo’s war-torn Kahele grapples with malnutrition, malariaon May 12, 2022 at 8:28 am
In Kalehe, a region of fertile hills dotted with villages in the eastern Democratic Republic of Congo (DRC), the gunfire was finally silenced last year after more than two decades of war. But while th ...
- USF technology identifies locations of mosquitoes and helps eradicate malariaon May 10, 2022 at 6:54 pm
Following his success eradicating a major source of malaria, technology created by a University of South Florida public health researcher is being implemented by insect control agencies throughout ...
- Smartphone app helps locate mosquitoes and combat malariaon May 10, 2022 at 1:52 pm
Following his success eradicating a major source of malaria, technology created by a University of South Florida public health researcher is being implemented by insect control agencies throughout ...
- Smartphone app helps locate mosquitoes, eradicate malariaon May 10, 2022 at 1:29 pm
As published in the American Journal of Entomology, University of South Florida researcher Benjamin Jacob discovered that each of the 120 homes he studied was infested with at least 200 mosquitoes.
- Malaria: Dramatic progress against this deadly disease has faltered. Here's how to get it back on track – Professor Heather M Fergusonon May 9, 2022 at 9:45 am
Twenty years ago, prospects for malaria control were bleak. The disease, caused by a parasite spread by mosquitoes, killed over one million every year, mostly young African children. The parasites had ...
- New Study Identifies Potential Immunotherapy Target for Malariaon May 9, 2022 at 7:00 am
A recently published article in Experimental Biology and Medicine (Volume 247, Issue 8, April, 2022) identifies ...
- Rollout of world's first malaria jab gathers paceon May 6, 2022 at 8:12 am
The world's first malaria vaccine will soon be available across sub-Saharan Africa, according to PATH, partners of the vaccine developers, as positive results from the pioneering jab pile up.
- Understanding How Malaria Parasites Develop Resistance to Drugson May 6, 2022 at 1:47 am
Researchers from The Australian National University (ANU) have discovered why malaria parasites are vulnerable to some drug therapies but resistant to others, offering scientists another piece of the ...
- World's first malaria vaccine may be available soon across Sub-Saharan Africaon May 5, 2022 at 7:26 pm
The world's first malaria vaccine will soon be available across Sub-Saharan Africa, according to PATH, partners of the vaccine developers, as positive results from the pioneering jab pile up.
via Google News and Bing News
